Development of biomarkers useful for early diagnosis and treatment optimization of ATTR amyloidosis

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09336
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurology
• Research Institution: Shinshu University
• Principal Investigator: Sekijima Yoshiki 信州大学, 学術研究院医学系, 准教授 (60322715)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: アミロイドーシス / トランスサイレチン

Outline of Final Research Achievements

We developed TTR oligomer assay system using antibody which specifically bind to misfolded TTR oligomer. By using this system, we showed that patients with ATTR amyloidosis have significantly higher level of serum misfolded TTR oligomer as compared with healthy controls and asymptomatic mutation carriers. In addition, we showed that treatment with liver transplantation or TTR tetramer stabilizers significantly decrease serum TTR oligomer level. We also showed that 11C-Pittsburgh compound B (PIB)-PET can detect ATTR amyloid deposition on barin, heart, stomach, spleen, lacrimal gland, salivary glands, thyroid gland, lymph nodes, skin, and muscle. These non-invasive biomarkers will be useful for early diagnosis and treatment optimization of ATTR amyloidosis.

Free Research Field

神経内科